Clinical Pharmacology

Unit

Clinical activity

The Clinical Pharmacology Unit provides services for inpatients and outpatients, both in agreement with the National Health Service and as private service.
It is specialised in quantifying plasma levels of numerous drugs of clinical importance:

  • Neurological (valproic acid, carbamazepine, phenytoin, phenobarbital, lacosamide, lamotrigine, levetiracetam, oxcarbazepine, peramapanel, topiramate, zonisamide)
  • Antiarrhythmics (amiodarone / desethylamiodarone)
  • Antifugals (posaconazole, isavuconazole, voriconazole)
  • Onco-haematology (methotrexate)
  • Polymorphisms detections of DPYD gene
    In compliance with recommendation from the Italian Association of Medical Oncology (AIOM) and the Italian Society of Pharmacology (SIF), the Clinical Pharmacology Unit of Campus Bio-Medico University Hospital performs a test that characterizes the risk of toxicity from antineoplastic fluoropyrimidines, such as 5-fluorouracil and capecitabine.
    The test identifies some polymorphisms of dihydropyrimidine dehydrogenase (DPD), the enzyme that breaks down fluoropyrimidines. If present, such polymorphisms can cause reduced activity of DPD and may expose patients to the risk of toxicity related to fluoropyrimidines. The test therefore allows oncologists to tailor the treatment to the patient's characteristics. The Clinical Pharmacology Unit adopts advanced technological instrumentations and uses only validated and certified diagnostic kits.  Furthermore, the Clinical Pharmacology Unit constantly undergoes Italian and European programs of Quality Controls.
    The DPYD test is made available by the Regional Health System.
    For information, please contact 06 22541 1115, Monday to Friday, from 10.00 am to 1.00 pm.

The Clinical Pharmacology Unit also provides espertise for Ethics Committees, Phase I Clinical Research, Pharmacotherapeutic advise.

Research fields

  • Validation and development of new methods of Tandem Mass Spectrometry for drug matrix dosing and metabolomics of clinical importance
  • Clinical and preclinical pharmacokinetics and pharmacodynamics of cancer drugs

The Unit is internationally known for

  • Cardiovascular toxicity of cancer drugs
  • Translational models of human heart exposure to cancer drugs
  • Clinical pharmacokinetic determinants of cancer drugs efficacy and safety

Clinical and research collaborations

  • Incyte BioSciences Europe
  • EUREKA Lab Division s.r.l.